Flawless clinical profiles cannot salvage a drug from manufacturing facility failures.
Even when therapeutic candidates demonstrate stellar clinical safety and efficacy, the FDA will block approval based entirely on quality control and facility deficiencies at manufacturing partners.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Sobi's gout therapy was rejected by the FDA entirely due to contract manufacturing site deficiencies, despite demonstrating a flawless clinical safety and efficacy profile.
The FDA rejected cytisinicline solely due to manufacturing issues at its third-party partner, despite having no concerns with the drug's safety or efficacy.
Unicycive's clinically viable kidney drug was blocked by a second consecutive FDA rejection due to unresolved compliance issues at its third-party manufacturer.
ITM's highly anticipated cancer therapy was rejected by the FDA solely over third-party facility issues, leaving its robust Phase 3 clinical package temporarily useless.
The FDA issued a third rejection for the camrelizumab-rivoceranib combination based entirely on manufacturing facility compliance issues, leaving the robust clinical efficacy data unquestioned.
Even with the FDA raising no questions about clinical data, bioequivalence, or stability, a manufacturing partner's facility deficiencies repeatedly block approval.
The FDA issued a fourth regulatory rejection for Dasynoc based entirely on CDMO manufacturing deficiencies, despite raising zero concerns about the drug's bioequivalence or clinical efficacy.
The FDA issued a Complete Response Letter rejecting the drug entirely due to third-party facility and manufacturing compliance issues, despite acceptable clinical safety and efficacy.
Outstanding facility compliance issues at a contract manufacturer triggered a fourth rejection, bypassing the drug's solid clinical data.
To prevent its stellar clinical profile from being derailed by a partner facility's regulatory infractions, Scholar Rock proactively excised the troubled Catalent plant from its BLA.
Deficiencies at a contract manufacturing facility forced the company to completely withdraw its European regulatory application despite strong clinical data.
Despite strong clinical prospects, Scholar Rock had to withdraw its European application because its third-party fill-finish facility failed to meet Good Manufacturing Practice standards.
A candidate with completed Phase 3 evidence was blocked purely on manufacturing grounds — the facility-failure veto operating exactly as the law describes.